Can we predict the prognosis of resectable hepatoblastoma from serum alpha-fetoprotein response during preoperative chemotherapy?
作者： Hiroaki Fukuzawa , Naoto Urushihara , Koji Fukumoto , Maki Mitsunaga , Kentaro Watanabe
DOI: 10.1007/S00383-012-3139-X
关键词:
摘要: Purpose The objective of this study was to clarify whether the alpha-fetoprotein (AFP) reduction rate during preoperative chemotherapy represents a prognostic factor for hepatoblastoma.
springer.com
sci-hub.se 参考文章(16)
Jörg Fuchs, Jana Rydzynski, Dietrich Von Schweinitz, Udo Bode, Hartmut Hecker, Peter Weinel, Dietrich Bürger, Dieter Harms, Rudolf Erttmann, Karl Oldhafer, Hermann Mildenberger, , Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer. ,vol. 95, pp. 172- 182 ,(2002) , 10.1002/CNCR.10632
Tadashi Matsunaga, Fumiaki Sasaki, Mutsuro Ohira, Kohei Hashizume, Akira Hayashi, Yutaka Hayashi, Hideo Mugishima, Naomi Ohnuma, Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma Pediatric Surgery International. ,vol. 19, pp. 142- 146 ,(2003) , 10.1007/S00383-002-0906-0
G. Perilongo, E. Shafford, R. Maibach, D. Aronson, L. Brugières, P. Brock, M. Childs, P. Czauderna, G. MacKinlay, J.B. Otte, J. Pritchard, R. Rondelli, M. Scopinaro, C. Staalman, J. Plaschkes, Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2. European Journal of Cancer. ,vol. 40, pp. 411- 421 ,(2004) , 10.1016/J.EJCA.2003.06.003
J M Van Tornout, J D Buckley, J J Quinn, J H Feusner, M D Krailo, D R King, G D Hammond, J A Ortega, Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children's Cancer Group. Journal of Clinical Oncology. ,vol. 15, pp. 1190- 1197 ,(1997) , 10.1200/JCO.1997.15.3.1190
Peter Schmittenbecher, Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma:T. Matsunaga, F. Sasaki, M. Ohira, et al. Pediatr Surg Int 19:142–146, (May), 2003 Journal of Pediatric Surgery. ,vol. 39, pp. 789- 790 ,(2004) , 10.1016/J.JPEDSURG.2004.03.024
Kyung Nam Koh, Meerim Park, Bo Eun Kim, Keun Wook Bae, Kyung Mo Kim, Ho Joon Im, Jong Jin Seo, Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma. Pediatric Blood & Cancer. ,vol. 57, pp. 554- 560 ,(2011) , 10.1002/PBC.23069
Sung-Eun Jung, Ki-Hong Kim, Min-Young Kim, Dae-Yeon Kim, Seong-Cheol Lee, Kwi-Won Park, Woo-Ki Kim, Clinical characteristics and prognosis of patients with hepatoblastoma. World Journal of Surgery. ,vol. 25, pp. 126- 130 ,(2001) , 10.1007/S002680020052
Maretta De Ioris, Laurence Brugieres, Arthur Zimmermann, Jean Keeling, Penelope Brock, Rudolf Maibach, Jon Pritchard, Liz Shafford, Joszef Zsiros, Piotr Czaudzerna, Giorgio Perilongo, Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: The SIOPEL group experience European Journal of Cancer. ,vol. 44, pp. 545- 550 ,(2008) , 10.1016/J.EJCA.2007.11.022
Tomoro Hishiki, Tadashi Matsunaga, Fumiaki Sasaki, Michihiro Yano, Kohmei Ida, Hiroshi Horie, Satoshi Kondo, Ken-Ichiro Watanabe, Takaharu Oue, Tatsuro Tajiri, Arata Kamimatsuse, Naomi Ohnuma, Eiso Hiyama, Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT Pediatric Surgery International. ,vol. 27, pp. 1- 8 ,(2011) , 10.1007/S00383-010-2708-0
Howard M. Katzenstein, Wendy B. London, Edwin C. Douglass, Marleta Reynolds, Jack Plaschkes, Milton J. Finegold, Laura C. Bowman, Treatment of Unresectable and Metastatic Hepatoblastoma: A Pediatric Oncology Group Phase II Study Journal of Clinical Oncology. ,vol. 20, pp. 3438- 3444 ,(2002) , 10.1200/JCO.2002.07.400